Genmab — December 2016
-
Second line approval came three weeks into November. I doubt that patients (customers) lined up Janssen's the very next day. I'm afraid that you are expecting too much of the November numbers. Nonetheless, the future looks bright.
-
Godmorgen, lad os håbe på den negative tendens stopper i dag
-
Godmorgen, den positive tendens kommer tilbage i 2017 i takt med bedre og bedre salgstal + diverse updates af resten af pipelinen. Hvade forventer at see kurs 1500 i 2016 men nu tror jeg vi vil se genmab stige 50-100% i 2017, nu hvor vi nok ikke ser mere end ca. 20% i 2016. 2017 burde vi runde 2000kr - tror vi vil se darzalex salg for +100M usd fra Januar og maaske stige 10% fra maaned til maaned
-
God morgen.
-
Vil sige det er fair nok at berige sig selv ovenpå gode resultater, men timingen er helt horribel.
-
Good morning. It is only Jan and David that got a really big bonus here, and, to be fair, they are absolutely key players for Genmab at the moment. I have no problem keeping them happy and commited to stay. Just imagine what Jan leaving could do to stock prices...
-
Det er udelukkende en moralsk snak, som også flere pensionskasser har påpeget over for Genmab. Skal jan have 0,5 mio i løn om dagen eller 1 mio om dagen. Hvad er rimeligt. Hvornår ændre lønninger karakter fra noget man fortjener og til tyveri fra aktieejerne? Jeg skal ikke dømme, men det er det der er i spil..
-
I totally agree with you E L
-
Danske Banks toppicks for 2017: B&O, DSV, GENMAB, NKT, PANDORA
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind